发现部门

噬菌体呈现以及酵母呈现
4月30日～5月1日

利用噬菌体呈现与酵母呈现的抗体制作方法，透过定向进化，分离几乎可对应所有受体的高亲合力蛋白质配位基，配合此目的，不断地改良以及修正。利用呈现法，可以制作高品质的抗体基因库，并筛检出成为病因的标的。本学会有利用高通量基因定序技术提高基因库的多样性与深度，和使用各种基准来选出高发展性等的方法。利用可获得结晶结构的想法，逐渐成为对应生物制剂设计方法的方针。为了掌握该领域的研究朝向哪个方向发展，置入此重要的蛋白质设计领域最新成果的计画建立变得非常重要。

第1天 | 第2天

4月29日, 星期日

4:00 - 6:00 pm Main Conference Registration

4月30日, 星期一

7:00 am Registration and Morning Coffee

B CELL CLONING

9:40 B Cell Display: Screening the Native Human B Cell Repertoire for Broadly Crossreactive Antibodies against the Influenza A Virus

Minha Park, Ph.D., Scientist, Antibody Discovery & B Cell Immunology, Trellis Bioscience

The human B cell repertoire represents a rich library of antibodies that have been naturally selected for high affinity, stability, and lack of off-target reactivity against human antigens, and therefore, less likely to cause immunogenicity when used as therapeutic agents. However, the low frequency of B cells expressing high quality antigen-specific antibodies has posed a barrier to discovery. Here, we show successful application of the Trellis Cellspot platform of single cell phenotyping to recover rare human B cells expressing high affinity and broadly crossreactive antibodies against the influenza A virus.

10:10 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

IN VIVO HALF-LIFE EXTENSION

11:10 Engineering Super Albumin for Improving Serum Half-Life

Chaity Chaudhury, Ph.D., Scientist, Antibody Discovery & Protein Engineering, MedImmune LLC

FcRn binds both IgG and albumin and diverts them from the lysosomal degredation pathway thus enhancing their lifespan. While FcRn mediated half-life extension through Fc has been engineered extensively, pH dependent affinity maturation of albumin to improve serum half-life remains laregely unexplored. We have engineered human albumin to improve its affinity for FcRn while retaining the pH dependence of binding through off rate engineering to extend lifespan of non-antibody therapeutics.

11:40 Use of pH Dependent Binding of Engineered Antibodies with Improved in vivo Half-Life Extension

E. Sally Ward, Ph.D., Paul and Betty Meek-FINA Professorship, Molecular Immunology, Cancer Immunobiology Center, University of Texas Southwestern

FcRn plays a central role in regulating the transport and distribution of IgG in the body. The presentation will cover recent developments in understanding FcRn function, combined with engineering FcRn-Fc interactions to generate therapies for autoimmune disease.

Sponsored by
12:10 pm Advances in Albumin Half-Life Extension Platform Translates to Positive Pharmacokinetic Studies

Mark Perkins, Ph.D., Technical Solution Specialist, Novozymes Biopharma

The ability to enhance the therapeutic half-life of drugs by conjugation or fusion to albumin is now well established. We have shown that albumin can be further enhanced for uses in drug delivery by manipulating its interaction with the neonatal Fc receptor (FcRn) via the introduction of specific amino acid changes in the albumin sequence. This talk will highlight a novel albumin platform and will include new pharmacokinetic data demonstrating the extended circulatory half-life of the albumin variants and protein drugs linked to such variants.

12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

EPITOPE MAPPING WITH CRYSTALLIZATION AND DISPLAY

2:00 Chairperson's Remarks

David Lowe, Ph.D., Fellow, R&D, MedImmune UK

2:05 Phage Selection of Bicyclic Peptides

Christian Heinis, Ph.D., Laboratory of Therapeutic Peptides and Proteins, Ecole Polytechnique Federal de Lausanne (EPFL)

My laboratory is generating bicyclic peptide ligands with high affinity and specificity for disease targets using a phage display-based approach that I had developed with Sir Greg Winter at the Laboratory of Molecular Biology (LMB) in Cambridge, UK (1). I will present the structure of a target-bound bicyclic peptide, new bicyclic peptide formats as well as first in vivo data.

2:35 Synthetic Antibodies: Structure and Function

Sachdev Sidhu, Ph.D., Associate Professor, Medical Research, University of Toronto

Synthetic antibody libraries have simplified the discovery of antibodies for structural studies. Synthetic antibody libraries are highly versatile for generating antibodies against diverse antigens. Moreover, synthetic antibodies exhibit superior performance in crystallization studies due to their stable nature.

3:05 Optimizing Functional Modules of Bispecific Antibodies Using Yeast Display Platform

Lihui Xu, Ph.D., Principal Scientist, Merrimack Pharmaceuticals

We developed a yeast display platform that combines the features of surface display and soluble expression within the single system, in conjunction with small structure-guided antibody library and innovative screening strategy, we are able to discover optimal functional modules in single campaign for a bispecific antibody that targets two Growth Factor Receptors.

3:35 State of the Art Epitope Mapping and Insights Gained from mAb-Target Co-Crystal Structures

Andrew Buchanan, Ph.D., Senior Scientist, Protein Engineering, MedImmune Ltd.

Examples of co-crystal structures will be used to provide insight into the antibody mechanism of action, species cross reactivity and the characteristics of the antibody paratope. In addition, alternative methods of epitope mapping will be illustrated.

4:05 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Problem Solving Breakout Discussions

5:45-6:45 Welcome Reception in the Exhibit Hall with Poster Viewing

第1天 | 第2天